NEW WORLD SYNDROME (OBESITY) GONE BY GUGGUL: A REVIEW

Kapil Deo Yadav, Anand Kumar Chaudhary

Abstract


Background: Obesity is multi factorial disease, defined as a state of imbalance between calories ingested versus calories expended would lead to excessive or abnormal fat accumulation. Its prevalence is on continuous rise in all age groups of the developed as well as developing countries in the world and it can be described as the "New World syndrome". Chronic inflammation, oxidative stress and hyperlipedimia play significant role in pathogenesis of obesity. Aim & Objective: To assess effect of Guggul on New World Syndrome. Material & Methods: References of Guggul are search out in classical as well as contemporary science in new world syndrome. Observation: During survey of Ayurvedic literature it was observed that different herbs, metals, minerals are used for treatment of obesity as single drug as well as in compound formulations. Among herbs Guggul occupied significant position and effectively used for treatment of obesity. It is oleogum resin, obtained from Commiphora mukul originate in India, Bangladesh and Pakistan having anti hyperlipidemic, anti oxidant, anti inflammatory property which is opposite to causative agent of obesity. Besides this Guggul also act as drug delivery medium and help in transportation of anti obesity agent to target site and performing their action when used with other anti obesity drugs. Conclusion: Guggul is effective in New World syndrome and probably acting by different pharmacological properties.



Keywords


Obesity, Guggul, Hyperlipidemic, anti oxidant, anti inflammation

References


Haslam DW, James WP. Obesity. Lancet. 2005;366 (9492):1197-209.

Taylor RW, Keil D, Gold EJ, Williams SM, Goulding A: Body mass index, waist girth and waist-to-hip ratio as indexes of total and regional adiposity in women: evaluation using receiver operating characteristic curves. Am J Clin Nutr 1998, 67:44-49.

Jacob CS, Katherine MH: Assessing obesity classification and epidemology. Br Med Bull 1997; 2:239

Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome The Lancet, 2005;365:1415-28

Satyavati GV. Effect of an indigenous drug on disorders of lipid metabolism with special reference to atherosclerosis and obesity (Medoroga) M.D. thesis (Doctor of Ayurvedic Medicine). Banaras Hindu University, Varanasi 1966

Charak. Commentary: Charak Chandrika of Brahmanand Tripathi on Charak Samhita of Charak, Sutra Sthan Chapter 25 verse no. 40 Varanasi, Chaukhambha Surbharti 2003;454.

Sushrut. Commentary: Ayurvedtatva Santipika of Shastri Ambikadatt on Sushrut Samhita by Ambikadatta Shastri Chikitas Sthan Chapter 5 verse no 35, Varanasi Chaukhambha Sanskrit Sansthan 2012:45

Arya VP. Gugulipid. Drug Fut 1988; 13:618-19.

Satyavati GV. Gum Guggul (Commiphora mukul)–The success story of an ancient insight leading to a modern discovery. Indian J Med Res 1988;87:327-35

Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 1994;8:659-64

Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002; 296:1703-06.

Wu J, Xia C, Meier J, Li S, Hu X, Lala DS. The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor. Mol Endocrinol 2002;16:1590-97

Ory DS. Nuclear receptor signalling in the control of cholesterol homeostasis: Have the orphans found a home? Circ Res 2004;95:660-70.

Kalaany NY, Mangelsdorf DJ. LXR (farnesoid X receptor) and FXR (Liver X receptors): The yin and yang of cholesterol and fat metabolism. Annu Rev Physiol 2006; 68:159-91.

Cai SY, Boyer JL. FXR: A target for cholestatic syndromes? Expert Opin Ther Targets 2006;10:409-21

Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem 2003;72:137-74

Kumari K, Augusti KT. Lipid lowering effect of S-methyl cysteine sulfoxide from Allium cepa Linn in high cholesterol diet fed rats. J Ethnopharmacol 2007;109:367-71

Fuchs M. Bile acid regulation of hepatic physiology: III. Regulation of bile acid synthesis: past progress and future challenges. Am J Physiol Gastrointest Liver Physiol 2003;284:G551-57

Deng R,Yang D, Radke A, Yang J, Yan B. The hypolipidemic agent guggulsterone regulates the expression of human bile salt export pump: Dominance of trans activation over farsenoid X receptor-mediated antagonism. J Pharmacol Exp Ther 2007;320:1153-1162

Wang P, Mariman E, Renes J, Keijer J. The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol 2008; 216:3-13.

Cherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55:1537-45.

Halberg N, Wernstedt-Asterholm I, Scherer PE. The adipocyte as an endocrine cell. Endocrinol Metab Clin N Am 2008;37:753–768

Konstantin Beier, Alfred Wlkl and M. Dariush Fahimi Suppression of peroxisomal lipid P-oxidation enzymes by TNF-a FEBS Letters 1992;310: 273-76

N Manjula, B. Gayathri, K.S. Vinaykumar, N.P. Shankernarayanan, R.A. Vishwakarma, A. Balakrishnan, Inhibition of MAP kinases by crude extract and pure compound isolated from Commiphora mukul leads to down regulation of TNF-a, IL-1h and IL-2 International Immunopharmacology 2006;6:122-32

Waggiallah H, Alzohairy M. The effect of oxidative stress on human red cells glutathione peroxidise, glutathione reductase level and prevalence of anemia among diabetics. N Am J Med Sci 2011;3:344-7

Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42

Singh RB, Niaz MA, Ghosh S. Hypolipidemic and antioxidant effects of Commiphora mukul as an adjunct to dietary therapy in patients with hypercholesterolemia. Cardiovasc Drugs Ther 1994; 8:659-64.

Singh K, Chander R, Kapoor NK. Guggulsterone, a potent hypolipidaemic, prevents oxidation of low density lipoprotein. Phytother Res1997;11:291-94

Meselhy MR. Inhibition of LPS-induced NO production by the oleogum resin of Commiphora wightii and its constituents. Phytochemistry 2003; 62:213-18

Saxena G, Singh SP, Pal R, Singh S, Pratap R, Nath C. Gugulipid, an extract of Commiphora whighitii with lipid-lowering properties, has protective effects against streptozotocin-induced memory deficits in mice. Pharmacol Biochem Behav 2007;86:797-805

Kaul S, Kapoor NK. Reversal of changes of lipid peroxide, xanthine oxidase and superoxide dismutase by cardio-protective drugs in isoproterenol induced myocardial necrosis in rats. Indian J Exp Biol 1989;27:625-27

Konstantin Beier, Alfred Wlkl and M. Dariush Fahimi Suppression of peroxisomal lipid P-oxidation enzymes by TNF-a FEBS letters 1992;310 273-76

Gujral ML, Sareen K, Tangri KK, Amma MK, Roy AK. Antiarthritic and anti-inflammatory activity of gum Guggul (Balsamodendron mukul Hook). Indian J Physiol Pharmacol 1960;4:267-73

Sharma JN, Sharma JN. Comparison of the anti-inflammatory activity of Commiphora mukul (an indigenous drug) with those of phenylbutazone and ibuprofen in experimental arthritis induced by mycobacterial adjuvant. Arzneimittelforschung 1977; 27:1455-57

Shishodia S, Aggarwal BB. Guggulsterone inhibits NF-kappa B and IkappaBalpha kinase activation, suppresses expression of anti-apoptotic gene products, and enhances apoptosis. J Biol Chem 2004; 279:47148-58.

Ichikawa H, Aggarwal BB. Guggulsterone inhibits osteoclastogenesis induced by receptor activator of nuclear factor-kappaB ligand and by tumor cells by suppressing nuclear factor-kappaB activation. Clin Cancer Res 2006; 12:662-68.

Cheon JH, Kim JS, Kim JM, Kim N, Jung HC, Song IS. Plant sterol guggulsterone inhibits nuclear factor kappa B signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis. Inflamm Bowel Dis 2006;12:1152-1161

H. Reithmeier, J. Herrmann, A. G opferich. Development and characterization of lipid microparticles as a drug carrier for somatostatin Int J Pharm 2001;218:133-43,

C. Schwarz, W. Mehnert, J. S. Lucks, and R. H. Muller. Solid lipid nanopar-ticles (SLN) for controlled drug delivery. I. Production, characterization and sterilization Journal of Controlled Release, 1994; 30:83–96

C Puglia and F. Bonina. Lipid nanoparticles as novel delivery systems for cosmetics and dermal pharmaceuticals. Expert Opinion on Drug Delivery 2012;9: 429-41

Gaur PK, Mishra S, Purohit S. Solid Lipid Nanoparticles of Guggul lipid as drug carrier for Transdermal drug delivery Biomed Res Int 2013;2013:1-10

Rolland A. Pharmaceutical particulate carrier, therapeutic application, Marcel Dekker. USA 2002; 61:1-10

Singh N, Chaudhary A. A Comparative review study of Sneha Kalpana (Paka) vis-a-vis liposome AYU 2011;32:103-08

Blume G, Cevc G. Drug-Carrier and Stability Properties of The Long-Lived Lipid Vesicles, Cryptosomes, In-vitro and In-vivo. J Liposome Res 1992;2:355-68

Liu DZ, Chen WY, Tsai LM, Yang SP. Microcalorimetric and shear studies on the effects of cholesterol on the physical stability of lipid vesicles. Colloids and Surfaces A: Physico chem Eng Aspects. 2000; 172:57-67.

Ahmad MU, Ali SM, Ahmad A, Sheikh S, Ahmad I. Guggulipid derivatives: synthesis and applications. Chem Phys Lipids. 2010;163:362-66

Dave V, Yadav S, Sharma S, Panwar N. Guggulusome - A Novel Vesicular Carriers for Enhanced Transdermal Delivery Iraqi J Pharm Sci 2014;.23:73-82


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.